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NATURAL OCCURRENCE, BIOLOGICAL ACTIVITIES AND SYNTHESIS OF EIGHT-, NINE-, AND ELEVEN-MEMBERED
RING LACTONES. The natural occurrence, biological activities and synthetic approaches to natural eight-, nine-, and eleven-
membered lactones is reviewed. These medium ring lactones are grouped according to ring size, and their syntheses are discussed.
The structures of some natural products early identified as medium-ring lactones were revised after total synthesis.
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INTRODUCTION
About ten years ago, Kao et al.1 wrote: “The chemical synthesis
of functionalized eight-membered ring lactones (2-oxocanones) is
extremely challenging, and virtually no functionalized eight-
membered ring lactones are known among natural products.” In
fact, these lactones, as well as those of nine- and eleven-membered
ring, are not so abundant in the Nature as their congeners containing
a ten-membered ring.2
Recently, the synthetic approaches toward the naturally
occurring ten-membered ring lactones (decalactones) were revised
by us.3 More specifically, Riatto et al.4 reviewed the synthetic studies
of decarestrictine family, an important class of decalactones.
Another recent review, dealing with the total syntheses of some
eight- and nine-membered ring lactones, was published by Shiina.5
Herein, we wish to review the natural occurrence and biological
activities of the eight-, nine- and eleven-membered ring lactones,
and to summarize the approaches for their syntheses. For those
syntheses already reviewed somewhere else, only a brief discussion
of the lactonization step will be presented here, in order to provide a
global panorama to the reader. Beyond the scope of this review are
the synthetic unnatural eight-, nine- and eleven-membered lactones.
EIGHT-MEMBERED RING LACTONES
Penicillide and derivatives
The dibenzodioxocanone named (+)-penicillide (1) was first
isolated in 1974, by Sassa et al.,6 from Penicillium sp. Later, this
metabolite was found, along with dehydroisopenicillide (2), in the
extract of Talaromyces derxii, and its absolute configuration was
established.7 In 1992, Proksa et al.8 reported the isolation of the
metabolites vermixocins A and B, from P. vermiculatum. Recently,
the structures of vermixocins A and B were determined as being
the same as those of penicillide (1) and (-)-purpactin A (3),
respectively, which were isolated from P. simplicissimum.9 Purpactin
A (3) was also isolated from P. purpurogenum in 1991, and showed
inhibitory effect of acyl-CoA-colesterol acyltransferase, an enzyme
involved in choslesterol ester accumulation in atherogenesis and in
cholesterol absorption from the intestines.10
Penicillide (1) and several related compounds were shown to be
antagonists of the peptide hormone oxytocin11 as well as inhibitors of
cholesterol ester transfer protein (CETP). Inhibition of CETP may have
a beneficial action in enhancing high-density lipoprotein cholesterol
(HDL) levels.12 Epidemiological studies show that low levels of HDL
is a risk factor for the development of coronary heart diseases.
Although several research groups deal with the biological
aspects of penicillide and its derivatives,11 there is no report, to our
knowledge, concerning the total synthesis of these compounds.
Ovatolide
(-)-Ovatolide (4) is a tetracyclic indole alkaloid bearing an eight-
membered ether-lactone, found in the leaves of Bridelia ovata, a
Thailandian plant used in folk medicine as laxative, febrifuge and
adstringent.13
A total synthesis of (-)-4 was developed by Delgado and Clardy,13
as summarized in Scheme 1. The β-glucosidic linkage of 6 was
constructed via the reaction of the 4-hydroxy-5-(benzyloxy)indole
derived from 5 with the epoxysugar 9, in a regio- and stereocontrolled
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manner. The authors used the Corey-Nicolaou protocol14 in the
lactonization step, and the eight-membered lactone 8 was obtained in
72% yield after treatment of 7 with 2,2’-dipyridyl disulfide (pySSpy)
and triphenylphospine. Deprotection of indole nitrogen atom and
hydroxyl groups of the glucoside subunit led to (-)-ovatolide (4).
Cephalosporolides
A group of five lactones, called cephalosporolides B-F (10-14),
was produced by fermentation of the fungus Cephalosporium
aphidicola, and their structures were elucidated by Ackland et al., in
1985.15 Later, cephalosporolide G (15) was isolated from the same
fungus by Farooq et al.,16 along with the known decalactone
diplodialide B17 and Z-3-methylpent-2-en-1,5-dioic acid. More
recently, Li et al.18 reported the isolation of cephalosporolides H
(16) and I (17) from lyophilized culture broth of the fungus Penicillium
sp. Three of these metabolites are ten-membered ring lactones
(cephalosporolides B, C and G), one is an eight-membered ring
lactone (cephalosporolide D), and the others (cephalosporolides E,
F, H and I) are spiroketal lactones.
According to the authors,15 cephalosporolides E (13) and F (14)
are probably artefacts of the isolation procedure, arose from
cephalosporolide C (11) through a sequence involving an opening
of the ten-memebred ring of 11 followed by relactonization and
acetal formation.
In 2005, Oller-López et al.19 isolated 13 and 14 in the broth
culture of the entomoparasitic deuteromycete Beauveria bassiana
and found a biosynthetic precursor of these lactones, the
butyrolactone bassianolone, which showed antimicrobial activity
against gram-positive cocci and fungi. To our knowledge, the
biological activities of cephalosporolides were not yet evaluated.
The only reported synthesis of (-)-cephalosporolide D (12),
allowing the determination of its relative and absolute stereochemistry,
was developed by Shiina et al.20 The lactonization of the hydroxy-
acids 18a/18b were performed employing different protocols. The use
of Hf(OTf)4 as Lewis acid catalyst and p-trifluoromethylbenzoic
Scheme 1. Reagents and conditions: (a) i: NaOH-Na2S2O4, DMF, 5 oC, 15
min, ii: 15-crown-5, epoxysugar 9, DMF, rt, overnight; (b) TFAA, DMF, 5 oC,
1 h; (c) NaH, THF, 0 oC, 15 min, then 0.5 N sol. of SEMCl in THF (1.5 equiv.),
5 oC, 30 min; (d) NaH, DMF, 70 oC, 15 min; (e) i: pySSpy, PPh3, CH2Cl2, rt 30
min, ii: AgClO4, benzene, reflux, 45 min; (f) MS 4A, THF, NH2CH2CH2NH2,
TBAF, 60 oC, 3 h; (g) Pd(OH)2, EtOAc, AcOH, H2, rt, 2 h
anhydride led to the corresponding eight-membered lactones 19a/19b
in 81% yield (Scheme 2).
In 2001 Buszek et al.21 synthesized the unnatural (+)-
cepalosporolide D (ent-12) using the Corey-Nicolaou lactonization
method14 (Scheme 3).
Octalactins
In 1991, the isolation and relative configurations of two lactones,
named octalactins A (20) and B (21), were reported by Tapiolas et al.22
These highly functionalized eight-membered ring compounds are
produced by an actinomycete collected from the surface of a mexican
gorgonian octocoral of the genus Pacifigorgia. Octalactin A (20) showed
significant in vitro cytotoxicity against some tumor cell lines, while
its olefin analogue B was inactive in the cytotoxic assays.
The four total syntheses of octalactins found in the literature,23-26
as well as some formal syntheses and related model studies,27 were
exhaustively discussed by Shiina, in his recent review.5 Therefore,
only some aspects of the total synthesis will be briefly depicted here.
The first synthesis of both octalactins A (20) and B (21), which
establishes their absolute configurations, was performed by Buszek
et al.23 The sequence involves as key step an intramolecular
esterification of the ω-hydroxy carboxylic acid 22, using a slight
Scheme 2. Reagents and conditions: (a) Hf(OTf)4, (p-CF3C6H4CO)2O, CH3CN,
THF, reflux (2.34 mM, slow addition over 15 h period; 81% yield based on
83% conversion); (b) i: H2, Pd/C, EtOH, rt (4/6 mixture of 12/ent-12); ii:
recristallization from hexanes
Scheme 3. Reagents and conditions: (a) pySSpy, PPh3, CH2Cl2, rt, 2 h, then
AgBF4, toluene, reflux, 12 h (81%); (b) DDQ, CH2Cl2, H2O (yield not given)
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modification of the Corey-Nicolaou protocol,14 which led to the
eight-memebred intermediate 23 in 73% yield (Scheme 4). Thus,
23 could be transformed into (-)-20 and (-)-21 after 7 and 6
additional steps, respectively.
McWilliams and Clardy24 reported a total synthesis of the
unnatural (+)-octalactin A (ent-20) and (+)-octalactin B (ent-21),
using a Baeyer-Villiger expansion of the cycloheptanone derivative
24 using unbuffered trifluoroperoxyacetic acid (Scheme 5).
The asymmetric total synthesis of both octalactins A and B has
also been achieved by O’Sullivan et al. in 2004.25 The eight-memebred
lactone core (27a or 27b) was obtained by Claisen rearrangement of
alkenyl-substituted cyclic ketene acetal, generated in situ by selenoxide
elimination of the corresponding selenoacetal 25 or by olefination of
the corresponding carbonate 26 using dimethyltitanocene (Scheme 6).
Shiina et al.26 recently reported the synthesis of (-)-octalactin A
(20) employing a mixed-anhydride lactonization approach to construct
the eight-membered ring moiety. Treatment of seco acid 28 with 2-
methyl-6-nitrobenzoic anhydride (MNBA) and a catalytic amount
of 4-(dimethylamino)pyridine (DMAP) or 4-(dimethylamino)pyridine
1-oxide (DMAPO) afforded the eight-membered lactone 29 in 90%
yield (Scheme 7).
More recently, an approach to the functionalized eight-membered
ring core of octalactins, based on a sequential Evans-Tishchenko
and ring closing metathesis (RCM) reactions, was developed by Aird
et al.28 The synthesis initially relied on the preparation of chiral
aldehydes 30 and 31, and phosphonate 33, as outlined in Scheme 8.
Horner-Wadsworth-Emmons reaction of 31 and 33, followed by
desilylation, furnished the β-hydroxy enone 34 as a 95:5 mixture of
the E/Z isomers. Evans-Tishchenko coupling of fragment 34 with
aldehyde 30, using preformed samarium(III) catalyst, led to dienoic
ester 35 as a single diastereomer. RCM reaction of 35, using second
generation Grubbs catalyst and Ti(OiPr)4 as Lewis acid, afforded a
1:1 mixture of the eight-membered lactone 37 and the cyclopentene
derivative 36, formed due to a competitive metathesis reaction of the
trisubstituted double bond in 35.
Solandelactones
The solandelactones A-I (38-46) constitute a group of eight-
membered ring lactones isolated in 1996 from Solanderia secun-
da, a dark-brown hydroid found in the shore of Jaeju Island, in
Korea. Solandelactones C (40), D (41), and G (44) exhibit moderate
inhibitory activity against FPT (farnesyl protein transferase).29
These compounds are lactonized cyclopropyl docosanoids,
being probably the first examples of marine oxylipins bearing a
C22 carbon skeleton. The biosynthetically related six-membered
ring constanolactones A and B30 and nine-membered ring
halicholactones (described further) are derived from eicosanoid (C20)
Scheme 4. Reagents and conditions: (a) H2, Pd/C; (b) i: pySSpy, PPh3, CH2Cl2,
rt, 8 h; ii: AgBF4, toluene, 110 oC, 96 h
Scheme 5. Reagents and conditions: (a) i: HF, CH3CN, rt, 15 h; ii: 3 M
CF3CO3H, CH2Cl2, -10 oC, 91 h
Scheme 6. Reagents and conditions: (a) NaIO4, NaHCO3, MeOH, H2O, 22 oC,
1,5 h; (b) 1-tert-butyldimethylsiloxy-1-methoxy-ethene, xylene, K2CO3, sealed
tube, 180 oC, 2,5 h; (c) Cp2TiMe2, toluene, reflux, 30 min
Scheme 7. Reagents and conditions: (a) MNBA, DMAP (10 mol%) or DMAPO
(10 mol%), Et3N, CH2Cl2, rt
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precursors. The original assigment of C11 of solandelactones E
(42) and F (43) was recently revised by total synthesis.31,32
Two different approaches to the synthesis of the cyclopropyl-
lactone segment of solandelactones were developed by Varadarajan
et al.33 Both strategies were based on the preparation of cyclopropane
derivatives 50a/50b, starting from 2,3-O-isopropylidene D-
glyceraldehyde 47 (Scheme 9). Then, 51 could be converted into
the eight-membered ring core of solandelactones (52) via a
lactonization key step, under Yamaguchi conditions,34 or through a
ring-closing metathesis of the dienoic ester 53 (Scheme 10).
The first total synthesis of a solandelactone was recently reported
by Davoren and Martin31 (Scheme 11). The authors synthesized the
solandelactone E (42) and revised the original assignment for C11. Thus,
2,3-O-isopropylidene glyceraldehyde 49 was converted in the diene 53,
which was selectively dihydroxylated using AD-mix β to furnish the
diol 54 as a single diastereomer. A thirteen-step sequence of reactions
led to the seco acid 55, which could be submitted to the Yamaguchi
lactonization protocol,34 followed by TBAF-mediated deprotection of
TBS ethers, affording the eight-membered lactone 56. The 1,3-
transposition of the C12 allylic alcohol could be achieved by treatment of
56 with o-nitrophenylselenocyanate and tri-n-butylphosphine, leading
to the activation and inversion of the less-hindered alcohol to furnish a
Scheme 8. Reagents and conditions: (a) i: t-BuOK, THF, trans-2-butene, n-BuLi, -78 → -45 oC, 20 min; ii: (-)-Ipc2BOMe, THF, -78 oC, 35 min; iii: BF3.OEt2, THF,
-78 oC, 4 h; (b) DDQ, MS 4A, CH2Cl2, 0 oC, 15 min; (c) DIBAL-H, CH2Cl2, 0 oC, 2 h; (d) (COCl)2, DMSO, CH2Cl2, Et3N, -78 oC → rt, 75 min; (e) PMBCl, t-BuOK,
DMF, rt, 3 h; (f) cat. OsO4, NaIO4, THF:H2O (4:1) rt, 2 h; (g) i: (cHex)2BOTf, Et3N, CH2Cl2, -78 oC, 2 h; ii: acrolein, -78 → 0 oC, 2 h; (h) TBSOTf, 2,6-lutidine,
CH2Cl2, 0 oC, 70 min; (i) i: (OEt)2P(O)CH2CH3; n-BuLi, THF, -78 oC, 1 h; ii: solution of 32 in THF, -78 oC, 1 h; (j) i: Ba(OH)2.8H2O, THF, rt, 30 min; ii: aldehyde
31, THF:H2O (40:1), rt, 24 h; (k) HF, CH3CN, rt, 15 min; (l) (PhCHO)2SmI.SmI3 (30 mol%), aldehyde 30, THF, -10 oC, 30 min; (m) 2nd generation Grubbs
catalyst, CH2Cl2, Ti(Oi-Pr)4, reflux, 24 h (36/37 = 1/1)
Scheme 9. Reagents and conditions: (a) Ph3P=CHCO2Et, benzene, 90 oC,
6 h; (b) DIBAL-H, CH2Cl2, -78→ 0 oC, 1 h; (c) TBDPSCl, imidazole, CH2Cl2,
0 oC → rt, overnight; (d) Et2Zn, CH2I2, CH2Cl2, -78 oC, 4 h, then 0 oC, 20 h; (e)
TBAF, THF, 0 oC, 1 h, then rt, overnight; (f) IBX, DMSO, THF, rt 6 h; (g)
H2C=CHCH2MgBr, Et2O, rt, 3 h; (h) Candida cylindracea lipase (CCL),
H2C=C(CH3)OAc, hexane, rt, 24 h; (i) DEAD, PPh3, gl. AcOH, THF, 0 oC →
rt, overnight
Scheme 10. Reagents and conditions: (a) cat. OsO4, NMO, acetone; (b) silica gel
impregnated with NaIO4, CH2Cl2; (c) BrPh3PCH2CH2CO2OEt, NaHMDS, THF, -
78 oC → rt; (d) LiOH, MeOH, THF/H2O, rt; (e) 2,4,6-trichlorobenzoyl chloride,
Et3N, DMAP, toluene, reflux; (f) H2C=CHCH2CH2C(O)Cl, Et3N, CH2Cl2, 0 oC →
rt; (g) 2nd generation Grubbs catalyst, CH2Cl2, Ti(OiPr)4, reflux, 50 h
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selenide, which was converted into the solandelactone E (42) after
hydrogen peroxide-mediated oxidation followed by a [2,3]-sigmatropic
rearrangement of the intermediate allylic selenoxide.
Recently, White et al.32 reported the synthesis of solandelactones
E (42) and F (43) and confirmed the hydroxyl configuration at C11,
early revised by Davoren and Martin.31 The synthesis starts with an
asymmetric aldol reaction between the titanium enolate derived from
58 and the achiral aldehyde 57, followed by cyclopropanation of the
Weinreb amide 59 to furnish the cyclopropane intermediate 60 as a
single diastereomer (Scheme 12). Conversion of 60 to the key cyclic
carbonate 61 was achieved in five steps. Olefination of 61, followed
by a Holmes-Claisen rearrangement of the corresponding ketene
acetal, led to the desired eight-membered lactone core of
solandelactones 62. Coupling of 63 with the acyclic side chain
fragment 64 (obtained from (S)-methyl 3,4-dihydroxybutanoate in
nine steps) using NHK reaction led to a mixture of C11 epimeric
solandelactones E (42) and F (43), in a 3.5:1 ratio, respectively.
Terpenoids
Some terpenoids bearing an eight-membered ring lactone are
described in literature, such as the sesquiterpenes schkuhripinnatolides
A-C (65-67), which were isolated from the aerial parts of Schkuhria
pinnata collected from Namibia.35
Scheme 11. Reagents and conditions: (a) trans-(EtO)2P(O)CH2CH=CHCO2Et, LDA, THF, 0 °C (10/1 EE/EZ); (b) Et2Zn, CH2I2, 65 °C, 4 h then 5 °C, 12 h; (c)
DIBAL-H, CH2Cl2, -78 °C; (d) TPAP, NMO, CH2Cl2, rt; (e) (EtO)2P(O)CH2CO2Et, NaH, THF, 0 °C (10:1 E/Z); (f) K3Fe(CN)6, K2CO3, K2OsO2(OH)4, (DHQD)2PHAL,
CH3SO2NH2, t-BuOH/H2O, rt; (g) TBSCl, imidazole, DMF, rt; (h) DIBAL-H, CH2Cl2, -78 °C → rt; (i) CBr4, PPh3, CH2Cl2, rt; (j) n-BuLi, 1-heptyne, CuBr.SMe2,
-78 °C; (k) TFA, H2O, CH2Cl2, rt; (l) NaH, 1-tosylimidazole, THF, 0 °C; (m) i: THPO(CH2)3CºCH, n-BuLi, -78 °C, 1 h; ii: BF3.OEt2, THF, -78 °C, 45 min, then -
100 °C, 2 h; (n) Ac2O, DMAP, Et3N, CH2Cl2, rt, 3.5 h; (o) p-TsOH, i-PrOH, rt; (p) H2, Lindlar catalyst, quinoline, MeOH, rt; (q) SO3.Py, Et3N, DMSO, CH2Cl2,
rt; (r) NaClO2, NaHPO4, 2-methyl-2-butene, t-BuOH, H2O, rt; (s) K2CO3, MeOH, rt; (t) 2,4,6-trichlorobenzoyl chloride, Et3N, DMAP, toluene, reflux; (u) TBAF,
THF, rt; (v) o-NO2PhSeCN, Bu3P, THF, rt, 1 h; (x) H2O2, Py, CH2Cl2, 0 °C, 5 h
A new unusual sesquiterpene lactone, named amygdalactone (68),
was isolated from the hulls of almond (Prunus amygdalus).36
Amygdalactone represents a new class of sesquiterpene bearing an
octalactone ring system. The cytotoxicity of this compound toward
K562, P3HR-1 and CEM leukemia cancer cell lines was evaluated
and the results showed very low inhibition rate. There is no synthesis
described.
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Examples of eight-membered diterpenoid lactones includes the
bis-homoditerpenes isoterracinolides A (69) and B (70) (from
Euphorbia terracina L.),37 and the cembrane diterpenes
echinodolides A (71) and B (72), isolated from the Brazilian medi-
cinal plant Echinodorus macrophyllus (also known as “chapéu-de-
couro”),38 used in traditional medicine in the treatment of hepatitis
and rheumatism. To our knowledge, there is no report concerning
the synthesis and the biological activities of these compounds.
Astakolactin (73) is a sesterterpene isolated in 2003 from the
mediterranean sponge Cacospongia scalaris.39 To our knowledge,
neither biological tests nor synthetic studies for this metabolite are
reported.
Dimeric lactones
Recently, Dat et al.40 isolated the dimeric lactones ardimerin
(74) and ardimerin digallate (75) from the extracts of Ardisia
japonica, a plant used in Oriental traditional medicine as antitussive
and diuretic, as well as to stop uterine bleeding. The diolide 75
showed in vitro inhibitory effect of HIV-1 and HIV-2 RNase H
(IC50 of 1.5 and 1.1 μM, respectively).
Revised structures
The structures of some natural products early identified as being
eight-membered rings were revised later. Thus, the initially proposed
structures for puerosides A and B41, sophoroside A42 and speciosides
A and B43 were showed to be butenolides (Table 1).44
Scheme 12. Reagents and conditions: (a) 1-(4-isopropyl-2-thioxothiazolidin-3-yl)ethanone (58), TiCl4, i-Pr2NEt, CH2Cl2, -78 oC, 6 h; (b) MeONHMe.HCl,
imidazole, CH2Cl2, rt, 16 h; (c) Et2Zn, CH2I2, CH2Cl2, -15 oC → rt, 3 h; (d) TESOTf, 2,6-lutidine, CH2Cl2, 0 oC, 45 min; (e) DIBAL-H, THF, -78 oC, 10 min; (f)
H2C=CHMgBr, THF, -78 oC, 50 min; (g) AcOH/THF/H2O (6/2/1), rt, 1 h; (h) (Cl3CO)2CO, CH2Cl2, Et3N, Py, MS 4A, -78 oC, 30 min; (i) Cp2TiMe2, toluene, 100
oC, 2 h (absence of light); (j) toluene, 100 oC; (k) TBAF, THF, rt, 1 h; (l) TPAP, NMO, CH2Cl2, MS 4A, rt, 20 min; (m) CrCl2 (excess), cat. NiCl2, DMSO, rt, 18 h
Table 1. Revised structures for puerosides A and B, sophoroside A
and speciosides A and B43
Lactone R1 R2 R3
(-)-pueroside A glu6-rha H H
(-)-pueroside B glu Me glu
(+)-sophoroside A glu Me H
specioside A glu H H
specioside B H glu H
glu = glucose; rha = rhamnose.
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Similarly, the structures of gonioheptolides A (76) and B (77),
isolated in 1993 from the stem bark of Goniothalamus giganteus,45
were corrected some years later.46 Independently, Bermejo et al.47
have isolated from Goniothalamus arvensis two compounds with
spectroscopic data very similar to those observed for the
gonioheptolides, and called them almuheptolide A (78) and B (79).
These metabolites have been cited in some other papers,48,49 up to
2002, when a revision of the structure of 78 was also reported.50,51
NINE-MEMBERED RING LACTONES
Halicholactone and neohalicholactone
The eicosanoid oxylipins (-)-halicholactone (80) and (-)-
neohalicholactone (81) were isolated from the marine sponge
Halichondria okadai (Kadota) collected at Daiozaki, Japan.
Halicholactone (80) exhibited weak inhibitory activity against
lipoxygenase of guinea pig polymorphonuclear leukocytes.52
In 1991, the relative stereochemistry of all stereocenters of
neohalicholactone (81) has been determined by X-ray crystallography
as shown below.53 Some years later, Proteau et al.54 isolated 81 from
the brown alga Laminaria sinclairii, and its absolute configuration
was suggested to be the opposite to that previously postulated.
The three total syntheses55-57 of halicholactone (80) and
neohalicholactone (81) reported in literature will be briefly
presented here, since Shiina5 discussed them in details in his review.
A formal synthesis of 80 and 81 was described in 1998.58
Critcher et al.  reported the synthesis of the right-hand
hemisphere59 and the first asymmetric total synthesis of
halicholactone (80) and neohalicholactone (81),55 confirming the
original assignments of absolute configuration of the stereocenters
of 81 originally proposed by Yamada and Clardy.53 They also
demonstrated, through the preparation of diastereomers of 81,55
that the natural product isolated by Proteau et al.54 was, in fact, a
C15 epimer of this nine-membered lactone.
The synthetic strategy was based on the preparation of the key
intermediate 83. The lactonization of seco acid 82, using the
Yamaguchi protocol,34 led to the nine-membered ring lactone 83,
which could be transformed into (-)-halicholactone (80) and (-)-
neohalicholactone (81) in six additional steps (Scheme 13).
The others two synthetic approaches to (-)-halicholactone (80)
were reported by Takemoto et al.56 and Takahashi et al.57 The authors
used as key step the ring-closing metathesis of dienoic ester 84,
using first generation Grubbs catalyst and titanium isopropoxyde
as Lewis acid, to achieve the nine-membered lactone 85, which
could be converted into (-)-80 by hydrolysis of the acetyl protecting
groups (Scheme 14).
Topsentolides
Topsentolides A1, A2, B1, B2, B3, C1, and C2 (86-92) are oxylipins
isolated in 2006 from the marine sponge Topsentia sp.60 These
lactones exhibit moderate citotoxicity against human solid tumor
cell lines. According to the authors, the (+)-topsentolide C1 (91)
and (+)-topsentolide C2 (92) are suspected to be artefacts formed
during the extraction with methanol. Synthetic approaches to these
nine-membered lactones were not found in the literature.
Terpenoids
Isotrichogoniolide (93)61 and (+)-sinulariadiolide (94)62 are nine-
membered terpenoid lactones, isolated from Trichogonia sp and
from a coral of the genus Sinularia, respectively, and were not
synthesized yet.
Scheme 13. Reagents and conditions: (a) i: 2,4,6-trichorobenzoyl chloride,
THF, rt, 2 h; ii: DMAP, toluene, reflux, 6 h
Scheme 14. Reagents and conditions: (a) 1st generation Grubbs catalyst, Ti(Oi-
Pr)4, CH2Cl2 (0.1 mM), reflux, (72% in ref. 56 and 93% in ref. 57); (b) K2CO3,
MeOH, rt (61% in ref. 56 and 55% in ref. 57)
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Antimycins
The antimycin-A antibiotics are a series of nine-membered
dilactones, which were isolated from a number of Streptomyces strains
over many decades.63 A complex mixture of antimycins A1-A8 is a
specific inhibitor of the electron transfer activity of ubiquinol-
cytochrome c oxidoreductase.64 The antimicyns have also other
biological properties such as antifungal activity, inhibition of enzymatic
activity as well as the ability to induce the death of cancer cells.65
The main component of this family of peptide alkaloids is the
antimycin A3, which had been considered as an unique compound
until 1988, when analytical investigations using HPLC techniques
revealed that this natural product is, in fact, a mixture of the
antimycins (+)-A3a (95) and (+)-A3b (96).66 The slight difference
between these two nine-membered dilactones relied upon the ester
function at C8: (+)-95 is a sec-butyl ester while the (+)-96 is the
isobutyl analog.
Both racemic67 and stereoselective synthesis68 of natural (+)-
antimycins A3b (96) have been first accomplished by Kinoshita et
al. Tsunoda group developed an asymmetric aza-Claisen
rearrangement of enolates of carboxamides and applied this
methodology to the synthesis of both, unnatural (-)-antimycin A3b69
(ent-96) and natural (+)-antimycin A3a70 (95), while one approach
for (+)-antimycin A3b (125) was recently reported.71 Some formal
synthesis of these dilactones are also found in the literature.72
Kinoshita et al.68 reported the first asymmetric total synthesis
of (+)-antimycin A3b (96) as well as the synthesis of one of its
diastereomers. Lactonization of (+)-(3S,4R,7R,8R,9S)-hydroxyacid
97a afforded the nine membered dilactone 98 in only ca. 1% yield.
A sequence of reactions on the amino group at the C3 position led
to the desired natural (+)-96 (Scheme 15).
Similarly, the authors could prepare the unnatural diastereomer
(-)-(3S,4R,7S,8S,9R)-100 of (+)-antimycins A3b, starting from the
hydroxyacid 97b (Scheme 16), following the same sequence of
reactions outlined in Scheme 15.68
The synthesis of unnatural (-)-antimycin A3b (ent-96) reported
by Tsunoda et al.69 started from (R)-(+)-methylbenzylamine, which
was transformed in the amide 101 in three steps. The aza-Claisen
rearrangement of 101 led the expected amide as a mixture of four
stereoisomers, from which the main isomers 102a and 102b could
be obtained as a unseparable 4:1 mixture, respectively.
Iodolactonization of 102a/102b, followed by reduction with n-
Bu3SnH, afforded the lactones 103a/103b, which was converted
into the desired prenyl ester 104a/104b along with the butenolide
by-product 105. Mitsunobu reaction73 of 104a/104b with N,O-
protected D-threonine (106) led to a mixture of the diesters 107a
and 107b. Hydrolysis of TBDMS and prenyl protecting groups was
easily achieved to furnish the seco acids 108a/108b, which was
submitted to the Corey-Nicolaou lactonization14 to afforded a
separable mixture of the nine-membered dilactones 109a/109b. The
unnatural (-)-antimycin A3b (ent-96) could then be obtained from
109a, after five additional steps (Scheme 17).
In 2003,70 the same Japanese group reported the stereoselective
synthesis of (+)-antimicym A3a (95) and established the absolute
configuration at the C2´ position on the acyloxy side chain. The
authors used (S)-(-)-methylbenzylamine for the preparation of the
seco acids 108c/108d, following the same sequence of reactions
early used for the synthesis of unnatural ent-96.69 Corey-Nicolaou
lactonization14 of 108c/108d, using Cu(OTf)2.PhH complex instead
the explosive AgClO4 metal salt, afforded a separable mixture of
the nine-memebered dilactones 109c/109d in 88% yield. Removal
of the TIPS-protecting group, followed by esterification of the free
hydroxyl group of 109c with (S)- and (R)-2-methylbutanoic acid
allowed the establishment of the S-configuration at the C2´ position
in the natural (+)-95 (Scheme 18).
More recently, Wu and Yang71 synthesized the (+)-antimycin
A3b (96) using a TiCl4-mediated asymmetric aldolization to construct
the C7/C8 stereocenters in 111 with the correct configurations. A
lactonization method,74 based on the activation of the acyl group
through the formation of w-hydroxyacid 112 (via the formation of
Scheme 15. Reagents and conditions: (a) i: TFA, rt, 10 min; ii: TTFA, benzene,
65-70 oC, 6 h; (b) palladium black, H2, MeOH, rt, 35 min; (c) i: O-benzyl-3-
nitrosalicylic acid N-hydroxysuccinimide ester (99), THF, 36 oC, 3 h; ii: Et3N
(pH=6), 36 oC, 25 h; (d) i: palladium black, H2, MeOH, rt, 10 min; ii:
dicyclohexylcarbodiimide (DCCI), THF, HCO2H, 0 oC, 4 h
Scheme 16
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Scheme 18. Reagents and conditions: (a) i: pySSpy, PPh3, benzene, 3 h; ii:
Cu(OTf)2.PhH, benzene, 80 oC, 3 h; (b) chromatographic separation (isolation
of 109c); (c) HF.Py, THF, 23 h; (d) (S)- and (R)-2-methylbutanoic acid, WSC,
DMAP, CH2Cl2; (e) H2, Pd/C, AcOEt; (f) 110, WSC, HOBt, NMM, DMF, rt;
(q) H2, Pd/C, AcOEt
Scheme 17. Reagents and conditions: (a) TMSOTf, DBU, ether, 0 ºC, 1 h; (b) TIPSOTf, acrolein, 0 ºC ’→ rt, 6 h; (c) CH3CH2CH2CH2CH2C(O)Cl, Et3N, CH2Cl2,
0 ºC; (d) i: LHMDS, toluene, -78 ºC; ii: 120 ºC, 6 h; (e) I2, N,N-dimethyl-p-nitroaniline, DME/H2O (3/2), rt, 3 days; (f) Bu3SnH, benzene, reflux; (g) i: CsOH, t-
BuOH, 0 ºC; ii: prenyl bromide, Py, ether, 0 ºC, 24 h, (h) 106, DEAD, PPh3, benzene, rt, 24 h; (i) 6 N aq. HCl, EtOH, rt, 24 h; (j) Pd(OAc)2, PPh3, Et3N, HCO2H,
dioxane, 100 ºC, 1 h; (k) i: pySSpy, PPh3, benzene, rt, 3 h; ii: AgClO4, benzene, 80 ºC, 2 h; (l) chromatographic separation (isolation of 109a); (m) TBAF, THF,
0 ºC, 5 min; (n) isovaleric anhydride, Py; (o) H2, Pd/C, AcOEt; (p) 110, water-soluble carbodiimide (WSC), 1-hydroxybenzotriazole (HOBt), N-methylmorpholine
(NMM), DMF, rt; (q) H2, Pd/C, AcOEt
a mixed anhydride after treatment with 2-methyl-6-nitrobenzoic
anhydride, MNBA), was used to construct the nine-membered
dilactone moiety (Scheme 19).
Griseoviridin
The macrocyclic peptide (-)-griseoviridin (115), isolated from
Streptomyces griseus, is a broad-spectrum antibiotic, with inhibitory
activity toward various pathogenic bacteria and fungi.75,76 This
alkaloid contains, among other functionalities, an unsaturated nine-
membered thioether-lactone subunit.
Several synthetic approaches to the sulfur-containing lactone
moiety of griseoviridin have been reported,77 and a total synthesis
of (-)-griseoviridin (115) was accomplished by Dvorak et al.78 in
2000 (Scheme 20). The authors used the RCM of 118, followed by
acid removal of the diol protecting group, to obtain the macrocycle
(-)-115 as a single diastereomer. It is noteworthy that the
lactonization of ω-hydroxyacid 116 to the nine-membered lactone
intermediate 117 (with inversion of the configuration of C5) was
easily achieved using the Mistunobu protocol.73
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Revised structures
In 1993, Cutler et al.79 isolated a bioactive product from a strain
of the fungus Botrytis cinerea and named it botcinolide. The structure
of this compound was determined as being a polyhydroxylated nine-
membered ring lactone (120a, Figure 1).80 A homologue of
botcinolide, called homobotcinolide (121a), was isolated by these
authors in 1996.81 The isolation of other botcinolide derivatives was
also reported by Collado et al.82,83
Tani et al.84 reinvestigated the spectroscopic data reported for
botcinolide and some derivatives, and revised their structures (Fi-
gure 1). They found that botcinolide, originally reported as the nine-
membered lactone 120a, is in fact the seco acid of botnicin E, as
well as the structure of 2-epibotcinolide (122a) was revised as being
the same as that of botcinin E (122b). In addition, botcinolide was
renamed botcinic acid (120b) and the name of homobotcinolide
was also changed to botcineric acid (121b).
An approach toward the synthesis of the lactone moiety of the
unnatural pseudo 2-epi-8-epibotcinolide was reported by
Chakraborty and Goswami.85
Independently, Shiina et al.86 recently achieved the total
synthesis of the pseudo 2-epibotcinolide (122a) and showed that
the proposed structures for this compound and related ones are
doubtful. The authors prepared the nine-membered lactone core
124 through the lactonization of seco acid 123 using MNBA as
activating reagent (Scheme 21). Epimerization of C2 in 125
smoothly took place on silica gel to afford the 2-epi-125 in 82%
yield. Deprotection of the diol at C4-C5 led to the unstable pseudo
2-epibotcinolide (122a), which underwent facile translactonization
to the corresponding γ-lactone 126.
Concerning the structural misassignments presented above, we
would like to reproduce some paragraphs of the fascinating work
of Nicolaou and Snyder,87 entitled Chasing Molecules That Were
Never There: Misassigned Natural Products and the Role of
Chemical Synthesis in Modern Structure Elucidation:
“Although the past half century has witnessed a remarkable
improvement in our ability to isolate and characterize complex
natural products, mistakes are still a relatively common occurrence.
Scheme19. Reagents and conditions: (a) i: TiCl4, TMEDA, CH2Cl2, -50 oC, 20
min, then -20 oC, 2 h; ii: TMEDA, -20 oC, 1 h; iii: TES-protected (S)-2-
hydroxypropanal (113), -20 oC, 2 h, then -5 oC, 6 h; (b) Me2CHCH2C(O)Cl,
Py, DMAP, CH2Cl2, 0 oC, 8 h; (c) BnOH, DMAP, CH2Cl2, rt, 32 h; (d) NaIO4,
THF/H2O (3/1), 0 oC, 3 h; (e) i: 114, DCC, CH2Cl2, 0 oC, 50 min; ii: DMAP, rt,
26 h; (f) H2 (30 atm), Pd(OH)2/C, MeOH, 40 oC, 8 h; (g) MNBA, DMAP,
toluene, MS 4A, rt, 23 h; (h) TFA, CH2Cl2, 20 oC, 9.5 h; (i) 110, 1-(3-
dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC.HCl), HOBt,
NMM, DMF, 30 oC, 23 h; (i) H2,10%  Pd/C, EtOAc, 30 oC, 6.5 h
Scheme 20. Reagents and conditions: (a) DIAD, PPh3, THF; (b) 10% Cd/ Pb,
1 M NH4OAc, THF; (c) 119, N’-(3-dimethylaminopropyl)-N-ethylcarbodiimide
(EDCI), HOBt, DMF; (d) Pd(PPh3)4 , pyrrolidine, H2C=CHCH2NH2, HOBt,
EDCI, DMF; (e) 1st generation Grubbs catalyst, toluene (0,001 M), 100 ºC; (f)
pyridinium-p-toluenesulfonate (PPTS), acetone/H2O
Figure 1. Botcinolide and analogues
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However (...) this state of affairs is far from catastrophic. Indeed,
structural misassignments clearly provide opportunities for synthetic
chemists to make discoveries through total synthesis, and certainly
show that there is still adventure to be had in the process of structure
assignment. (...) we can be certain that as long as chemists conti-
nue to isolate new and diverse substances from nature, there will
be plenty of challenges for our intellectual and physical skills.
Moreover, much new science awaits discovery during the struggle
to synthesize such new molecular puzzles”.
Eleven-membered ring lactones
Few examples of eleven-membered lactones are found in Nature,
similarly to what occurs with the eight- and nine-membered ones.
Besides some structurally more complex pyrrolizidinic and
daphniphyllum alkaloids, there are two insect pheromones - the
ferrulactone I and the suspensolide - and three fungal metabolites -
the aspercyclides A-C - described in the literature.
Ferrulactone I
In 1983, Wong et al.88 reported the isolation of two lactones from
the frass of Cryptolestes ferrugineus (Stephens), the rusty grain beetle.
These compounds, named ferrulactone I (127) and ferrulactone II
(128), are aggregation pheromones produced by the male insects,
and bear an eleven- and a twelve-membered ring lactone, respectively.
All the syntheses89-92 of ferrulactone I (127) described in literature
start from geraniol. The first synthesis of 127 was reported in 1983
by Oehlschlager et al.,89 which obtained the cyclic intermediate 132
by intramolecular alkylation of the ω-bromo-geraniol derivative 131.
This intermediate was prepared by reaction of geraniol 129 with
(phenylthio)acetyl chloride, followed by allylic oxidation in C8 and
bromination of the alcohol thus obtained. Finally, desulfurization of
132 afforded the target molecule in 10% global yield (Scheme 22).
In the same paper,89 an alternative approach to ferrulactone 127
was also described. The key step consists of an intramolecular
esterification93 of the dienoic acid 134, prepared by formal addition of
acetate anion equivalent to tetrahydropyranyl-protected 8(E)-bromo-
geraniol 133. The best yield obtained for the eleven-membered lactone
127 was 37%, when bis(4-tert-butyl-N-isopropylimidazol-2-yl)disulfide
(BID)93 was used as activating reagent and the temperature of the
reaction medium was carefully controlled (Scheme 23).
The cyclization of 135 under the action of zerovalent palladium,
followed by sodium amalgam-promoted desulfurization of the eleven-
membered lactone intermediate, also afforded the ferrulactone I (127),
as described by Kukovinets et al.90 (Scheme 24).
Another synthesis of 127 in which the key step is a lactonization
of a seco acid was reported by Cheskis et al.91 The Claisen
rearrangement of allylic alcohol 136 proceeded stereospecifically
to furnish the ester 137 in 95% yield as a single (E,E)-isomer
Scheme 21. Reagents and conditions: (a) MNBA, DMAP, CH2Cl2, rt, 4 h (7%
of the dimer of 124); (b) i: H2, Pd(OH)2, EtOH, rt, 15 h; ii: TPAP, NMO, MS
4A, CH2Cl2, 0 °C, 3 h (125/2-epi-125 = 8/2); (c) preparative TLC; (d) i: NaBH4,
MeOH, 0 °C, 2 h; ii: DHP, CSA, CH2Cl2, rt, 1 h; iii: TBAF, THF, 0 °C, 3 h; (e)
i: TBS-protected 4-(R)-2-(E)-4-hydroxyoct-2-enoic acid, MNBA, Et3N, DMAP,
CH2Cl2, rt, 3.5 h; ii: HF.Py, THF, rt, 3 h; (f) BBr3, CH2Cl2, - 45 °C, 1.5 h
Scheme 22. Reagents and conditions: (a) C6H5SCH2C(O)Cl, Py, CH2Cl2, 0
oC, 3 h; (b) SeO2, Py, EtOH, reflux, 4.5 h; (c) NaBH3C≡N, THF, 0 ºC, 1 h, then
23 °C for 18 h; (d) CBr4, PPh3, Et2O, 23 °C, 20 h; (e) NaH, HMPA, THF,
reflux, 23 h; (f) Ni-Ra, EtOH, rt, 1 h
Scheme 23. Reagents and conditions: (a) 2,4,4-trimethyl-2-oxozoline, n-BuLi,
THF, -78 °C, 1 h; (b) i: MeI (excess), rt; overnight; ii: 1 N aq. NaOH, rt, 20 h;
iii: Dowex 50W-X8, MeOH, rt, 1 h; (c) i: BID, PPh3, toluene, -68 oC → -10 oC,
2.5 h; ii: addition of cold toluene, -35 → 23oC, then reflux, 2 h
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(Scheme 25). Removal of THP protecting group followed by ester
hydrolysis led the ω-hydroxyacid 134, which was submitted to
latonization using BID, similarly to what was previously reported
by Oehlschlager et al.90
Moriya et al.92 obtained the ferrulactone (127) in a short four-
step synthesis, also starting from geraniol (Scheme 26). An
intramolecular Reformatsky reaction of ω-bromoacetoxy aldehyde
138 led to the eleven-membered lactone intermediate 139, which
was submitted to selective allylic debenzoylation promoted by SmI2
in THF-HMPA.
Suspensolide
Suspensolide (140), which is a regioisomer of ferrulactone I
(127), was isolated in 1988 from the male Caribbean fruit fly
Anastrepha suspensa (Loew), together with anastrephin (141) and
epianastrephin (142).94 Later, 140 was reported to be also produced
by A. ludens,95 and A. fraterculus.96
Studies concerning some biosynthetic aspects of suspensolide (140)
were published by Battiste et al.97 Thus, acid-catalyzed rearrangement
of 140 to anastrephin (141) and epianastrephin (142) was carried out
by treatment with BF3.Et2O, as depicted in Scheme 27.
The same authors98 developed a conformational analysis of
suspensolide (140), by molecular modeling and NMR studies, and
concluded that the two most stable conformers have the methyl
groups in a syn position.
The complete assignments of the 1H-NMR and 13C-NMR spectra
of the lactones suspensolide (140), anastrephin (141) and
epianastrephin (142) have been accomplished by Baker and Heath.99
Battiste et al.100 reported a short synthesis of suspensolide (140)
from mesityl oxide and proved the (3E,8E)-geometry of the double
bonds of this natural product. The key hydroxyacid 143 was
submitted to lactonization under Mitsunobu conditions73 to afford
140 in only 25% isolated yield (Scheme 28).
In the same year, Mori and Nakazono101 reported the synthesis
of 140 also using the Mitsunobu lactonization73 of 143, which
afforded the desired eleven-membered lactone in a very poor yield
(ca. 9%). The key hydroxyacid 143 was prepared from geraniol in
a fifteen-step sequence of reactions.
A stereospecific synthesis of suspensolide (140) was achieved
by Del Vecchio and Oelschlager.102 The synthesis started with 1,6-
heptadiyne which was converted into the diol 145 by a double
carboalumination with in situ conversion to a dialanate intermediate
followed by reaction with paraformaldehyde (Scheme 29). THP-
monoprotection of 145, conversion of free hydroxyl group to
chloride and cyanide substitution under phase-transfer conditions
led to the nitrile 146, which could not be directly hydrolyzed to the
corresponding carboxylic acid without isomerization of the double
bond. Thus, 146 was alternatively converted into the amide 147
followed by a very mild hydrolysis, leading to the desired acid
148. Lactonization of 143 under Mitsunobu conditions,73 as already
reported by Battiste et al.,100 also led to suspensolide 140 in poor
Scheme 24. Reagents and conditions: (a) i: NaH, THF, 0 °C, 15 min, then rt,
30 min. ii: Pd(PPh3)4 , bisdephenylphosphineethylene, 0 oC; (b) sodium
amalgam, EtOH, AcOH, - 20 °C →  rt, 2.5 h
Scheme 25. Reagents and conditions: (a) MCPBA, AcONa, CH2Cl2, 0 oC, 30
min, then 20 oC, 1.5 h; (b) (i-PrO)3Al, toluene, reflux, 6 h; (c) TMOF,
CH3CH2CO2H, 135 °C, 1.5 h; (d) PTSA, Py, EtOH, 55 °C, 4 h; (e) aq. KOH,
MeOH, rt, 1 h; (f) BID, toluene, PPh3, -75 °C, 30 min, then -10 °C, 1.5 h
Scheme 26. Reagents and conditions: (a) SmI2-THF, BzC(O)Cl, DMAP, rt;
(b) SmI2-THF-HMPA, 2,2-dimethyl propanoic acid, 0 °C
Scheme 27. Reagents and conditions: (a) BF3.EtO2, Et2O, 23 °C, 0.5 h
Scheme 28. Reagents and conditions: (a) DEAD, PPh3, benzene, rt, 72 h
Scheme 29. Reagents and conditions: (a) i: AlMe3, ZrCp2Cl2, ClCH2CH2Cl,
0 oC, 3 h; ii: n-BuLi, THF, (CHO2)n, -78 oC, overnight; (b) DHP, Et2O, PTSA,
rt; (c) NCS, CH2Cl2, DMS, 0 oC, 1 h; (d) KCN, CH3CN, 18-crown-6, rt, 12 h;
(e) H2O2, ,n-Bu4HSO4, CH2Cl2, 20% aq. NaOH, rt, 8 h; (f) Na2O2, H2O, 80 oC,
8 h; (g) AcOH/THF/Et2O (4/2/1), 45 oC, 4 h
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yield (30%), along with a mixture of anastrephin (141) and
epianastrephin (142), in 40% isolated yield.
A stereoselective four-step synthesis of the 10-hydroxy-4,8-
dimethyl-3(E),8(E)-dienoic acid (143), precursor of suspensolide
(140), was described in 1996.103 The authors used the regioselective
oxidation of the methyl group of geranyl acetate 149 with selenium
oxide to obtain the aldehyde 150 in 53% yield. Wittig reaction
followed by saponification led to the trienoic acid 151, which could
be converted into the desired seco acid 143 by a regio- and
stereoselective reduction of the conjugated diene moiety with
lithium in liquid ammonia and methanol (Scheme 30).
It is of note that an eleven-membered lactone (2,4,6,8-
tetramethyl-3,4-dihydroxydec-8(9)-enolide), structurally related to
suspensolide, was recently isolated from the fungus Botrytis cynerea
(Figure 2), along with some botcinolide derivatives.83
Aspercyclides
Aspercyclides A-C (152-154) are biphenylether-lactones
isolated from an extract of Aspergillus sp.104 Aspercyclide A (152)
showed to be inhibitor of the IgE receptor binding (IC50 = 200 μM),
thus having a moderate anti-inflammatory effect. Compounds with
this biological action may be efficacious in the treatment of allergic
diseases such as asthma and rhinitis.
The first reported total synthesis of (+)-aspercyclide C (154)
was achieved by Fürstner and Müller105 through a kinetically
controlled RCM reaction to form the eleven-membered ring
(Scheme 31). The straightforward preparation of diaryl acid 155
was possible by an Ullmann coupling of a bromide with a phenol,
followed by saponification of the ester function. An anti-selective
oxy-allylation reaction led to the aliphatic fragment 156a, upon
treatment of PMP-protected allyl alcohol with hexanal, a strong
base and the (S,S)-158 complex. Esterification of acid 155 with
alcohol 156a was performed using the Mukaiyama method106 to
furnish the dienoic ester 157. RCM of 157 with second generation
Grubbs catalyst afforded the eleven-membered unsaturated lactones
as a 5:1 mixture of E and Z isomers, respectively. Chromatographic
separation followed by deprotection of hydroxyl groups of the E-
isomer led to the (+)-aspercyclide C (154).
Recently, a formal synthesis of (+)-aspercyclide C (154) was
reported.107 The preparation of the PMB-protected linear fragment
156a was done using D-ribose acetonide as chiral pool (Scheme
32). Monoprotection of diol 159 led to a mixture of products, from
which the desired product 156a could be isolated in only 41% yield.
Scheme 30. Reagents and conditions: (a) SeO2, EtOH, reflux, 1 h; (b)
Ph3P=CHCO2Et, 100 oC, 1 h; (c) KOH, H2O, MeOH, 23 oC, 72 h; (d) Li, liq.
NH3, MeOH, reflux, 15 min
Figure 2. 2,4,6,8-Tetramethyl-3,4-dihydroxydec-8(9)-enolide
Scheme 31. Reagents and conditions: (a) CuO, K2CO3, Py, 130 oC; (b) aq.
NaOH, MeOH; (c) i: sec-BuLi; ii: hexanal, complex (S,S)-158, THF/Et2O,
-78 oC; (d) N-methyl-2-chloropyridinium iodide, Et3N, CH3CN, reflux; (e) 2nd
generation Grubbs catalyst, toluene, reflux, (f) chromatographic separation;
(g) CAN, CH3CN/H2O, 0 oC; (h) BBr3, CH2Cl2, -78 → 0 oC
Scheme 32. Reagents and conditions: (a) Ph3PCH2CH2CH2CH3Br, t-BuOK,
THF, 0 oC → rt, 16 h; (b) Ra-Ni, H2, EtOH, rt; (c) i: MsCl, Et3N, CH2Cl2, 0 oC,
3 h; ii: Zn, NaI, DMF, 155 oC, 2 h; (d) PTSA, MeOH, rt, 24 h; (e) PMBCl,
NaH, DMF, 0 oC → rt, 10 h (20% recovery of 159); (f) ) N-methyl-2-
chloropyridinium iodide, Et3N, CH3CN, 120 oC, 1 h; (g) 2nd generation Grubbs
catalyst, toluene, reflux, 3 h; (h) BBr3, CH2Cl2, -78 oC, 5 min
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Mukaiyama coupling106 of alcohol 156a with acid 155 (see Scheme
31), second generation Grubbs catalyst-mediated RCM of the
dienoic ester intermediate and PMB-deprotection led to (+)-
aspercyclide C (154), following a similar sequence of reactions
early described by Fürstner and Müller.105
Alkaloids
In 2006, the alkaloid (+)-macropodumine A (160) was isolated
from the stem of Daphniphyllum macropodum, a plant used in
Chinese traditional medicine in the treatment of inflammations.108
This metabolite has a fused pentacyclic system including an eleven-
membered lactone, a structure feature never found before within
the Daphniphyllum alkaloid family.
Eight others Daphniphyllum alkaloids, namely macropodumines
B-I, have also been found in D. macropodum,109 but these molecules
are not medium ring lactones. To our knowledge, there are no synthetic
approaches for macropodumine A (160) described in the literature.
Some eleven-membered dilactone having a pyrrolizidine moiety
were isolated from several species of Crotalaria.110 The hepatotoxic
and carcinogenic monocrotaline (161) (Figure 3) is the most abundant
alkaloid in this family of secondary metabolites, being isolated from
C. lechnaultii,111 C. grahamiana,112 C. crispata,113 C. fulva114 and
several others species of this genus.115 Others representative examples
of the pyrrolizidine alkaloids with these structure features are
dicrolataline (162),116 fulvine (163), 113,114 and crispatine (164).111,114
The natural occurrence and biological properties of these eleven-
membered dilactones, among others pyrrolizidine compounds, were
reviewed in the series articles published in the journal Natural
Products Reports.117 The synthesis of 161-164118 and related
dilactone pyrrolizidine alkaloids will not be discussed here.
CONCLUSION
This review has attempted to summarize the natural occurrence,
the biological properties as well as the enormous efforts toward
the synthesis of the natural eight-, nine-, and eleven-membered
lactones known to date.
In contrast to what was stated by Kao in 1997,1 this challenging
class of natural products has been stimulating chemists to develop
new methodologies to construct the medium ring lactone core. Thus,
several successful syntheses of the title compounds can be found
in the literature.
It must be highlighted the increasing use of RCM to achieve
the medium ring lactones, as already observed for the synthetic
approaches to the ten-membered ring lactones, recently reviewed
by us.3 Nevertheless, the use of the lactonization methods developed
by Corey-Nicolaou,14 Yamaguchi34 and Mitsunobu73 is still
remarkable.
Although much success has been obtained in the syntheses
described here, many of the natural eight-, nine-, and eleven-
membered lactones have never been synthesized. Thus, we hope to
see new exciting synthetic studies reported soon.
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